HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia.

AuthorsQ Jiang, L-P Xu, D-H Liu, K-Y Liu, R P Gale, M-J Zhang, B Jiang, X-H Zhang, Y Wang, S-S Chen, X-Y Zhao, H Chen, H Jiang, Y-H Chen, W Han, Y-Z Qin, Y-R Liu, Y-Y Lai, M Lv, X-J Huang
JournalLeukemia (Leukemia) Vol. 27 Issue 12 Pg. 2410-3 (Dec 2013) ISSN: 1476-5551 [Electronic] England
PMID23698276 (Publication Type: Letter)
Chemical References
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
Topics
  • Adolescent
  • Adult
  • Antineoplastic Agents (therapeutic use)
  • Benzamides (therapeutic use)
  • Cohort Studies
  • Combined Modality Therapy
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, surgery)
  • Piperazines (therapeutic use)
  • Pyrimidines (therapeutic use)
  • Siblings
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: